AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...
Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...
Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...
Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...
News Medical on MSN4h
Globally prostate and testicular cancer rates climb, but mortality is fallingNew research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...
A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...
The FDA has granted a 510 (k) clearance to the Ibex Prostate Detect software (formerly Galen Second Read). The Ibex Prostate ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback